Last reviewed · How we verify

AboBoNT-A — Competitive Intelligence Brief

AboBoNT-A (AboBoNT-A) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum neurotoxin type A. Area: Neurology, Aesthetics, Pain Management.

marketed Botulinum neurotoxin type A SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Aesthetics, Pain Management Biologic Live · refreshed every 30 min

Target snapshot

AboBoNT-A (AboBoNT-A) — Ipsen. AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AboBoNT-A TARGET AboBoNT-A Ipsen marketed Botulinum neurotoxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum neurotoxin type A class)

  1. Ipsen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AboBoNT-A — Competitive Intelligence Brief. https://druglandscape.com/ci/abobont-a. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: